ALNY
Alnylam Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
ALNY fundamentals
Alnylam Pharmaceuticals (ALNY) released its earnings on Feb 12, 2026: revenue was 1.10B (YoY +84.95%), missed estimates; EPS was 0.82 (YoY +226.15%), missed estimates.
Revenue / YoY
1.10B
+84.95%
EPS / YoY
0.82
+226.15%
Report date
Feb 12, 2026
ALNY Earnings Call Summary for Q4,2025
- Record Revenue Growth: 2025 net product revenues reached $2.99 billion (+81% YoY), driven by TTR franchise expansion.
- GAAP Profitability Achieved: Full-year non-GAAP operating income of $850 million, marking a new era of sustained profitability.
- 2030 Ambitious Goals: 25% CAGR, 30% operating margin, and TTR market leadership by 2030.
- Pipeline Momentum: 40+ clinical programs, including Phase III studies for zilebesiran and nucresiran, with siRELIS manufacturing platform to reduce COGS.
- AMVUTTRA Dominance: 90% U.S. first-line coverage, near-parity new patient starts vs. tafamidis, and 95% TTR knockdown profile.
EPS
Actual | -1.62 | -1.56 | -2.18 | -2.09 | -1.71 | -1.61 | -1.72 | -2.16 | -2 | -2.29 | -3.32 | -1.68 | -1.4 | -2.21 | 1.15 | -1.1 | -0.52 | -0.13 | -0.87 | -0.65 | -0.44 | -0.51 | 1.84 | 0.82 | |||||||||||
Forecast | -1.885 | -1.7241 | -1.6271 | -1.7792 | -1.749 | -1.605 | -1.5369 | -1.5462 | -1.8087 | -1.5851 | -1.743 | -1.8593 | -1.6705 | -1.5059 | -1.4457 | -1.1864 | -1.116 | -1.067 | -0.9166 | -0.5921 | -0.89 | -0.5437 | 0.561 | 1.1559 | |||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +14.06% | +9.52% | -33.98% | -17.47% | +2.23% | -0.31% | -11.91% | -39.70% | -10.58% | -44.47% | -90.48% | +9.64% | +16.19% | -46.76% | +179.55% | +7.28% | +53.41% | +87.82% | +5.08% | -9.78% | +50.56% | +6.20% | +227.99% | -29.06% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 99.48M | 103.96M | 125.85M | 163.56M | 177.57M | 220.55M | 187.63M | 258.54M | 213.26M | 224.82M | 264.31M | 335.04M | 319.29M | 318.75M | 750.53M | 439.72M | 494.33M | 659.83M | 500.92M | 593.17M | 594.19M | 773.69M | 1.25B | 1.10B |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 91.74M | 98.76M | 119.05M | 146.64M | 168.50M | 192.05M | 218.72M | 233.61M | 240.95M | 255.56M | 291.66M | 313.13M | 312.27M | 332.28M | 396.76M | 436.92M | 428.01M | 447.22M | 532.91M | 582.61M | 585.14M | 662.87M | 959.40M | 1.15B |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +8.43% | +5.26% | +5.71% | +11.54% | +5.38% | +14.84% | -14.21% | +10.67% | -11.49% | -12.03% | -9.38% | +6.99% | +2.25% | -4.07% | +89.17% | +0.64% | +15.50% | +47.54% | -6.00% | +1.81% | +1.55% | +16.72% | +30.19% | -4.53% |
Earnings Call
You can ask Aime
What is Alnylam Pharmaceuticals's gross profit margin?What were the key takeaways from Alnylam Pharmaceuticals’s earnings call?What factors drove the changes in Alnylam Pharmaceuticals's revenue and profit?What is Alnylam Pharmaceuticals's latest dividend and current dividend yield?Did Alnylam Pharmaceuticals beat or miss consensus estimates last quarter?What does Alnylam Pharmaceuticals do and what are its main business segments?What guidance did Alnylam Pharmaceuticals's management provide for the next earnings period?What is the market's earnings forecast for Alnylam Pharmaceuticals next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
